REGENXBIO Inc. (NASDAQ:RGNX) Shares Bought by Texas Permanent School Fund

Texas Permanent School Fund raised its stake in REGENXBIO Inc. (NASDAQ:RGNXGet Rating) by 2.8% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 27,435 shares of the biotechnology company’s stock after acquiring an additional 752 shares during the period. Texas Permanent School Fund owned 0.06% of REGENXBIO worth $678,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently bought and sold shares of the stock. BlackRock Inc. boosted its stake in REGENXBIO by 0.3% in the first quarter. BlackRock Inc. now owns 6,588,815 shares of the biotechnology company’s stock valued at $218,683,000 after acquiring an additional 17,377 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of REGENXBIO by 0.4% during the first quarter. Vanguard Group Inc. now owns 4,070,462 shares of the biotechnology company’s stock worth $135,099,000 after buying an additional 16,496 shares during the period. State Street Corp boosted its stake in shares of REGENXBIO by 6.6% during the first quarter. State Street Corp now owns 2,653,766 shares of the biotechnology company’s stock worth $88,078,000 after buying an additional 163,513 shares during the period. Dimensional Fund Advisors LP boosted its stake in shares of REGENXBIO by 4.0% during the first quarter. Dimensional Fund Advisors LP now owns 779,142 shares of the biotechnology company’s stock worth $25,860,000 after buying an additional 29,670 shares during the period. Finally, First Manhattan Co. boosted its stake in shares of REGENXBIO by 17.8% during the first quarter. First Manhattan Co. now owns 696,365 shares of the biotechnology company’s stock worth $23,112,000 after buying an additional 105,305 shares during the period. Institutional investors and hedge funds own 83.25% of the company’s stock.

Insider Activity

In other news, CFO Vittal Vasista sold 2,400 shares of the stock in a transaction that occurred on Tuesday, August 30th. The shares were sold at an average price of $30.24, for a total value of $72,576.00. Following the sale, the chief financial officer now directly owns 135,160 shares in the company, valued at $4,087,238.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 12.70% of the company’s stock.

Wall Street Analysts Forecast Growth

RGNX has been the subject of several recent research reports. SVB Leerink increased their target price on shares of REGENXBIO from $13.00 to $14.00 and gave the stock a “market perform” rating in a research note on Friday, November 4th. TheStreet cut shares of REGENXBIO from a “c” rating to a “d+” rating in a report on Friday, November 4th. Morgan Stanley cut their price target on shares of REGENXBIO from $52.00 to $50.00 and set an “overweight” rating for the company in a report on Monday. StockNews.com began coverage on shares of REGENXBIO in a report on Wednesday, October 12th. They set a “hold” rating for the company. Finally, Royal Bank of Canada cut their price target on shares of REGENXBIO from $47.00 to $29.00 in a report on Tuesday, October 4th. Three investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, REGENXBIO currently has a consensus rating of “Moderate Buy” and a consensus target price of $41.43.

REGENXBIO Trading Down 0.2 %

Shares of REGENXBIO stock opened at $21.67 on Tuesday. REGENXBIO Inc. has a 12-month low of $18.69 and a 12-month high of $36.35. The stock has a market cap of $938.18 million, a PE ratio of 13.98 and a beta of 1.00. The company has a 50-day moving average of $23.14 and a two-hundred day moving average of $25.54.

REGENXBIO (NASDAQ:RGNXGet Rating) last released its quarterly earnings results on Thursday, November 3rd. The biotechnology company reported ($1.75) EPS for the quarter, missing the consensus estimate of ($1.55) by ($0.20). The business had revenue of $26.51 million during the quarter, compared to analyst estimates of $29.77 million. REGENXBIO had a net margin of 15.34% and a return on equity of 12.22%. On average, sell-side analysts forecast that REGENXBIO Inc. will post -5.34 EPS for the current fiscal year.

About REGENXBIO

(Get Rating)

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform.

See Also

Want to see what other hedge funds are holding RGNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for REGENXBIO Inc. (NASDAQ:RGNXGet Rating).

Institutional Ownership by Quarter for REGENXBIO (NASDAQ:RGNX)

Receive News & Ratings for REGENXBIO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REGENXBIO and related companies with MarketBeat.com's FREE daily email newsletter.